SMASH-VT Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Vivek Reddy Substrate Mapping and Ablation in Sinus Rhythm to Halt.

Slides:



Advertisements
Similar presentations
Agenda Introduction Classes of recommendations Level of evidence
Advertisements

ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,
The MADIT II Trial Multicenter Autonomic Defibrillator Implantation Trial II Presented at the American College of Cardiology 51st Annual Scientific Session.
Multicenter Automatic Defibrillator Implantation Trial II
EP Testing and Use of Devices in Heart Failure HFSA 2010 Recommendations.
Cardiac Insufficiency Bisoprolol Study (CIBIS III) Trial
INTRINSIC RV Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Brian Olshansky Inhibition of Unnecessary RV Pacing with AV.
Sudden Cardiac Death Prevention: Clinical Trials Alena Goldman, MD September 9, 2004.
Pexelizumab for the Reduction of Infarction and Mortality in Coronary Artery Bypass Graft ll (PRIMO-CABG II) Trial Presented at The American College of.
Paclitaxel-eluting Stents vs Brachytherapy for In-stent Restenosis (TAXUS V ISR) Trial Presented at The American College of Cardiology Scientific Session.
Myocardial Repair by Percutaneous Cell Transplantation of Autologous Skeletal Myoblast as a Stand Alone Procedure in Post Myocardial Infarction Chronic.
ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial The telmisartan trial in cardiovascular protection Sponsored by Boehringer.
Ventricular tachycardia in abnormal heart Dolly mathew.
MAIN-COMPARE Study Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease.
IMPANTABLE CARDIOVERTER DEFIBRILLATORS (ICDs) Janet McComb Freeman Hospital Newcastle upon Tyne.
Copyleft Clinical Trial Results. You Must Redistribute Slides SEISMIC Trial The Safetyand Effects of Implanted (Autologous) Skeletal Myoblasts (MyoCell)
The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.
Ablation for Paroxysmal Atrial Fibrillation (APAF) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Carlo.
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Sudden death as co-morbidity in patients following vascular intervention Sudden death as co-morbidity in patients following vascular intervention Impact.
Prognostic Value of Programmed Electrical Stimulation Among Implantable Cardioverter-Defibrillator Recipients Real-World Data from the Israeli National.
Indications of ICD in 2010 Dr Mervat Aboulmaaty Professor of Cardiology Ain Shams University DAF 1 st EP course 2010.
Arrhythmia Case Studies Content Courtesy of: John P. DiMarco, MD, PhD N.A. Mark Estes III, MD.
Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.
Ventricular Tachyarrhythmias
Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.
Randomized Angioplasty Beta Blocker Intracoronary Trial II (RABBIT II) Presented at The American Heart Association Scientific Session 2006 Presented by.
Presenter Disclosure Information John F. Beshai, MD RethinQ Trial Results Disclosures Information: The following relationships exist related to this presentation:
EP Laboratories in Korea 1610 patients in 1998 RF ablation1,034 cases EP study576 cases Seoul 9 수원 1 인천 1 대전 1 대구 3 부산 4 마산 1 광주 1.
Effects of PG , a Matrix Metalloproteinase Inhibitor to Prevent Left Ventricular Remodeling After Acute Myocardial Infarction Effects of PG ,
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.
IRIS Post-hoc Analysis Background IRIS compared the safety and efficacy of early ICD implantation with medical treatment alone in 898 patients at high.
Norwegian Vitamin Trial NORVITNORVIT Presented at The European Society of Cardiology Congress 2005 Presented by Dr. Kaare Harold Bønaa.
ARRHYTHMIA. Disturbance of cardiac rythumn Anatomy of the conducting system.
The Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented.
Atorvastatin for Reduction of Myocardial Dysrhythmias After Cardiac Surgery Trial Presented at The American College of Cardiology Scientific Sessions March.
SWEDMAF Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Carina Blomstrom-Lundqvist SWEDMAF Trial.
Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.
EP Show – Dec 2003 ICDs – Primary prevention The EP Show: Guidelines and reimbursement at the crossroads: Primary prevention with ICDs Eric Prystowsky.
A-4 Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Pierre Jais Atrial Fibrillation Ablation vs. Antiarrhythmic Drugs Trial.
European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.
Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure REMINDER* Gilles Montalescot, Bertram Pitt,
Complex Devices..... Biventricular Pacemaker: (aka Cardiac Resynchronisation Therapy) Treats subset of patients with heart failure Needs high quality.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Ventricular Arrhythmias:A General Cardiologist’s Assessment of Therapies in 2004 C.Richard Conti M.D. MACC.
Defibrillator in Acute Myocardial Infarction Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Drs. Stewart Connelly.
Ethical Scenario: Cardiovascular System
Total Occlusion Study of Canada (TOSCA-2) Trial
Sudden Cardiac Arrest Morhaf Ibrahim, MD, FHRS Electrophysiology.
University of Ottawa Heart Institute and Turku PET Centre
Implantable Defibrillator Therapy Post Cardiac Arrest
DANTE PAZZANESE INSTITUTE OF CARDIOLOGY, SÃO PAULO, BRAZIL
Defibrillator in Acute Myocardial Infarction Trial
Simon A. Castro, MD; Daniele Muser, MD; Erica Zado, PA; Rajeev K
American College of Cardiology Presented by Dr. Stuart J. Connolly
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
Aliskiren and Valsartan for Antihypertensive Therapy Trial
The most common cause of death in North America is cardiac death and the most common cause of cardiac death is sudden death from ventricular arrhythmias.
The EP show: sudden death, part 1 Director
Catheter Ablation for the Cure of Atrial Fibrillation Study
3 to 4 million patients fit the entry criteria
Management of refractory ventricular tachycardia due to cardiac sarcoidosis—A biologic approach  Joseph Theodore, MD, DM, Daljeet Kaur Saggu, MD, DM,
Challenges in the diagnosis and management of idiopathic ventricular fibrillation  Jonathan Lipton, MD, PhD, George J. Klein, MD, Raymond W. Sy, MBBS,
ARISE Trial Aggressive Reduction of Inflammation Stops Events
Failure of ICD therapy in lethal arrhythmogenic right ventricular cardiomyopathy type 5 caused by the TMEM43 p.Ser358Leu mutation  Kasper Aalbæk Kjærgaard,
The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter
Vivek Y. Reddy et al. JACEP 2019;j.jacep
Temporal trends of AF hospitalisation per 100 patients with AF according to main hospitalisation causes between 2006 and *P value for increase trends 
Survival free of atrial fibrillation after implantation of an implantable cardioverter defibrillator in our series (151 patients): overall population (solid.
Presentation transcript:

SMASH-VT Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Vivek Reddy Substrate Mapping and Ablation in Sinus Rhythm to Halt Ventricular Tachycardia Trial

SMASH-VT Trial: Background The goal of the trial was to evaluate treatment with ICD implantation with catheter ablation compared with ICD alone among post myocardial infarction (MI) patients with sustained ventricular tachycardia (VT)/ ventricular fibrillation (VF)The goal of the trial was to evaluate treatment with ICD implantation with catheter ablation compared with ICD alone among post myocardial infarction (MI) patients with sustained ventricular tachycardia (VT)/ ventricular fibrillation (VF) Presented at HRS 2006

SMASH-VT Trial: Study Design Presented at HRS 2006  Primary Endpoint: Appropriate ICD therapies ICD implantation with substrate-based catheter ablation n=62 n=62 ICD alone n=64 n= patients not using class l or lll antiarrhythmic drugs, prior MI, and either VF arrest, unstable VT, or prior ICD and single appropriate shock Randomized. 13% female, mean age 66 years, mean follow-up 2 years 71% NYHA Class ll, 18% NYHA Class lll, Mean EF 31.7% 18% had VF arrest, 52% had unstable VT, 21% had syncope and inducible VT and 9% had prior ICD and single appropriate shock, 96% received beta-blockers and 91% received ACE-inhibitors, index MI was anterior in 41% of patients and 67% had prior revascularization 126 patients not using class l or lll antiarrhythmic drugs, prior MI, and either VF arrest, unstable VT, or prior ICD and single appropriate shock Randomized. 13% female, mean age 66 years, mean follow-up 2 years 71% NYHA Class ll, 18% NYHA Class lll, Mean EF 31.7% 18% had VF arrest, 52% had unstable VT, 21% had syncope and inducible VT and 9% had prior ICD and single appropriate shock, 96% received beta-blockers and 91% received ACE-inhibitors, index MI was anterior in 41% of patients and 67% had prior revascularization  Ablation was performed with electroanatomic mapping to delineate the endocardial infarct margins  The radiofrequency ablation catheter used either a standard 4mm (n=10) or an irrigated 3.5 mm tip (n=52)  Ablation was performed with electroanatomic mapping to delineate the endocardial infarct margins  The radiofrequency ablation catheter used either a standard 4mm (n=10) or an irrigated 3.5 mm tip (n=52)

SMASH-VT Trial: Primary Endpoint Presented at HRS 2006 Primary endpoint of appropriate ICD therapy (%) p<0.05 Incidence of appropriate ICD shock (%) p<0.05 The primary endpoint of appropriate ICD therapy occurred less frequently in the ablation group compared with the control group (15% vs. 33% p=<0.05), as did appropriate ICD shock (10% vs. 33%, p=<0.05). The primary endpoint of appropriate ICD therapy occurred less frequently in the ablation group compared with the control group (15% vs. 33% p=<0.05), as did appropriate ICD shock (10% vs. 33%, p=<0.05).

SMASH-VT Trial: Adverse Events SMASH-VT Trial: Adverse Events Presented at HRS 2006 Mortality occurred in 7% of the ablation group and 17% of the control group (p=0.073).Mortality occurred in 7% of the ablation group and 17% of the control group (p=0.073). Among the adverse events in the ablation group, there was one pericardial effusion without tamponade, one deep vein thrombosis, and one CHF exacerbation.Among the adverse events in the ablation group, there was one pericardial effusion without tamponade, one deep vein thrombosis, and one CHF exacerbation. Mortality among both patient groups (%) p=0.073

SMASH-VT Trial: Summary Among post-MI patients with sustained VT/VF, ICD implantation with substrate-based catheter ablation was associated with a reduction in appropriate ICD therapy through two years compared with ICD therapy alone.Among post-MI patients with sustained VT/VF, ICD implantation with substrate-based catheter ablation was associated with a reduction in appropriate ICD therapy through two years compared with ICD therapy alone. The present trial suggests that the procedure can also be effective in reducing ICD shocks in the post-MI setting, although it should be noted that the procedure is difficult to perform and extremely technical, so use for prophylactic therapy should be undertaken with caution and only in experienced centers.The present trial suggests that the procedure can also be effective in reducing ICD shocks in the post-MI setting, although it should be noted that the procedure is difficult to perform and extremely technical, so use for prophylactic therapy should be undertaken with caution and only in experienced centers. Among post-MI patients with sustained VT/VF, ICD implantation with substrate-based catheter ablation was associated with a reduction in appropriate ICD therapy through two years compared with ICD therapy alone.Among post-MI patients with sustained VT/VF, ICD implantation with substrate-based catheter ablation was associated with a reduction in appropriate ICD therapy through two years compared with ICD therapy alone. The present trial suggests that the procedure can also be effective in reducing ICD shocks in the post-MI setting, although it should be noted that the procedure is difficult to perform and extremely technical, so use for prophylactic therapy should be undertaken with caution and only in experienced centers.The present trial suggests that the procedure can also be effective in reducing ICD shocks in the post-MI setting, although it should be noted that the procedure is difficult to perform and extremely technical, so use for prophylactic therapy should be undertaken with caution and only in experienced centers. Presented at HRS 2006